RxDoctor Payments Data

Christopher Madias, MD

Clinical Cardiac Electrophysiology · Boston, MANPI 1174647036

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boston Scientific at 32.4% of the total. Reporting peaked in 2024 at $3,877 and has fallen 54.7% since, to $1,755 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MA, where the typical reported total is $10,274.

$12,970in general payments, 2019–2025

Across 113 payments — averaging $114.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$3K
  • Medtronic$3K
  • Biosense Webster, Inc.$1K
  • Medical Device Business Services, Inc.$866
  • Biotronik Inc.$451
  • plus $458 from 5 others
$57,081in research payments, 2019–2025

Across 3 payments — averaging $19,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Irhythm Technologies, Inc.$51K
  • Abbott$7K

What the payments were for

  • Speaking & faculty fees$2,50019%
  • Travel & lodging$5,51343%
  • Food & beverage$4,95838%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,970 in reported general payments places this provider in the 50th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$177,784
Medicare patients
1,093
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$82,251
Metoprolol Succinate32$670
Flecainide Acetate13$638
Amiodarone Hcl22$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$82,25176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →